Combretum micranthum
Combretum micranthum · Accepted scientific name
Scientific literature: Very Sparse (2 studies) · ★☆☆☆☆
Combretum micranthum is a significant botanical species widely recognized for its diverse pharmacological properties. The plant's leaves are frequently utilized in various preparations, including aqueous leaf extracts, aqueous-methanol extracts, EECM, and capsules of plant powder. Research indicates that these preparations exhibit potent antidiabetic and antioxidant activities, making them valuable in medicinal applications. These biological effects are attributed to key chemical constituents such as 4-hydroxycinnamic acid, (-)-11-hydroxy-9,10-dihydrojasmonic acid, 3-deshydroxysappanol trimethyl ether, and 9,13-di-cis-retinoic acid. Beyond metabolic support, the plant is also studied for its potential therapeutic use in treating conditions like bronchitis and colitis.
- Synonyms
- Combretum Altum · Bureava Crotonoides · 3 more
- Common names
- Not available
- Family
- Combretaceae
- Distribution
- Not available
- Plant Parts
- Leaf
Classification
Common Names
Combretum micranthum is a versatile plant recognized by a wide variety of local and descriptive names. It is most frequently referred to as kinkeliba or kinkéliba, depending on the specific regional dialect used. In certain areas, the plant is also known by the common name Bute kabo. It is further identified as kɔ̀lɔ̀bɛ, reflecting its deep cultural roots in various communities. Additionally, its unique medicinal properties have earned it the distinctive moniker opium-antidote.
Sources: Catalogue of Life (COL)
Synonyms
Combretum micranthum is a botanical species known by several different scientific names in various taxonomic records. It is frequently identified by the synonym Bureava crotonoides in certain botanical contexts. The plant is also linked to the names Combretum altum and Combretum floribundum within existing literature. Furthermore, researchers may encounter this species listed as Combretum parviflorum or Combretum raimbaultii. Understanding these various synonyms is essential for accurate identification and consistent scientific study.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Combretum micranthum is a distinctive species belonging to the kingdom Plantae. Within this vast biological kingdom, the plant is classified under the class Equisetopsida. It specifically falls into the order Myrtales, showcasing its unique evolutionary lineage. The plant is a member of the Combretaceae family, which defines its broader botanical characteristics. Finally, it is categorized under the genus Combretum, placing it within a well-recognized group of flowering plants.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Myrtales |
| Family | Combretaceae |
| Genus | Combretum |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Combretum micranthum is a plant species primarily distributed across the diverse landscapes of West Tropical Africa. Its presence is widely documented throughout several key nations, including Benin and Burkina Faso. The species also thrives within the regional ecosystems of Gambia and Ghana. Furthermore, its natural habitat extends into the lush environments found in Guinea. This widespread distribution highlights the plant's significant ecological footprint across the West African subcontinent.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Combretum micranthum is a self-supporting shrub that establishes a sturdy presence in its natural habitat. This plant typically reaches a maximum height of 4 meters as it matures. Its compact growth form makes it a distinctive feature of the local landscape.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Combretum micranthum is a plant widely recognized for its significant ethno-medicinal uses in northwest Nigeria. Recent scientific investigations have successfully demonstrated that aqueous-methanol extracts of its leaves possess both antidiabetic and antioxidant activities. Through molecular docking studies, researchers identified several potentially active compounds that interact with key target proteins such as α-amylase and α-glucosidase. Specifically, compounds like 4-hydroxycinnamic acid and glyinflanin A showed promising binding scores and optimal drug-likeness characteristics. These findings suggest that the plant's bioactive constituents may serve as valuable candidates for future drug development.
Compounds
Combretum micranthum is a medicinal plant recognized for its significant antidiabetic and antioxidant properties in ethno-medicinal practices. Recent in silico studies have identified several key bioactive compounds within its aqueous-methanol leaf extracts. Specifically, the plant contains 3-deshydroxysappanol trimethyl ether, 4-hydroxycinnamic acid, colnelenic acid, and glyinflanin A. Molecular docking simulations revealed that these compounds demonstrate significant binding interactions with target proteins such as α-amylase and α-glucosidase. Because many of these constituents exhibit optimal drug-likeness and medicinal chemistry characteristics, they serve as promising candidates for future pharmaceutical development.
Conditions
Combretum micranthum demonstrates significant therapeutic potential by treating diabetes through its effective antihyperglycaemic and antidiabetic properties. The plant also serves as a promising candidate for the management of inflammatory bowel diseases (IBD), specifically by alleviating the clinical signs of acute colitis. Research indicates that its ethanolic extract is effective in mitigating DSS-induced ulcerative colitis through antioxidant and anti-inflammatory activities. Furthermore, the plant's leaf extract helps treat UV radiation irritation by enhancing cell survival and reducing the production of pro-inflammatory cytokines in skin cells. Together, these findings highlight the medicinal versatility of the species in addressing metabolic, gastrointestinal, and dermatological conditions.
Preparations
Combretum micranthum is prepared as an ethanolic extract, also referred to as EECM, which has shown potential in mitigating ulcerative colitis through antioxidant and anti-inflammatory activities. The plant is also processed as an aqueous leaf extract to investigate its antihyperglycaemic effects in diabetic models. Additionally, aqueous-methanol extracts of the plant are utilized for molecular docking studies to identify potentially active antidiabetic compounds. For clinical applications regarding hypertension, Combretum micranthum is administered in the galenic form of capsules of plant powder. These diverse preparation methods highlight the plant's versatility in various pharmacological research settings.
Parts used
Combretum micranthum, commonly known as kinkeliba, is a medicinal plant that derives much of its therapeutic value from its leaves. Research indicates that the aqueous leaf extract of this species possesses significant antihyperglycaemic properties, performing comparably to standard antidiabetic drugs in animal models. Furthermore, clinical trials have demonstrated that capsule forms of the powdered leaves can effectively help reduce both systolic and diastolic blood pressure in patients with hypertension. The chemical complexity of these leaves also makes them a subject of study for quality control through the chromatographic profiling of non-polar metabolites. Ultimately, the diverse medicinal applications of Combretum micranthum highlight the importance of the leaf as a vital component in African traditional medicine.